Blood cancers, Lymphoma
Open
Phase 2/3
This trial is looking at zilovertamab vedotin with a for people with diffuse large B cell lymphoma.
You pronounce zilovertamab vedotin as zi-lov-er-ta-mab veh-doh-tin.
It is open to people whose diffuse large B cell lymphoma (DLBCL) has come back after treatment (relapsed) or got worse during treatment (refractory).
Recruitment start: 4 October 2023
Recruitment end: 24 September 2027
Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.
Professor Satyen Gohil
Merck Sharp & Dohme Ltd
Last reviewed: 06 Oct 2025
CRUK internal database number: 19581
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
